GSK is two shots away from clean bill of health
One of Europe’s most cheaply valued drugmakers, the £75 bln group run by Luke Miels is turning a corner. Fears over expiring patents are easing thanks to a booming oncology unit. A £40 bln sales …
One of Europe’s most cheaply valued drugmakers, the £75 bln group run by Luke Miels is turning a corner. Fears over expiring patents are easing thanks to a booming oncology unit. A £40 bln sales …